BioPharma Clinical Trials
NK010 exhibits multiple high anti-tumor advantages including wide spectrum and high expression of NK cell activation receptors and high purity, which makes...
January 23, 2024 | News
The Progeria Research Foundation (PRF) today announced a new milestone with the approval of Zokinvy™ (lonafarnib) by the Japanese Ministry of Health,...
January 22, 2024 | News
The primary objective of the RESET trial was to collect data to support a planned FDA regulatory submission, paving the way for the marketing and distribut...
January 17, 2024 | News
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignan...
January 16, 2024 | News
This study is led by Professor Rodney Sinclair and included 12 male and 4 female patients in Australia with androgenic alopecia (AGA). ...
January 15, 2024 | News
CLIMB is a US based, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety, tolerability and efficacy of ARINA-1 in participant...
January 12, 2024 | News
mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia. ...
January 11, 2024 | News
-Medidata, a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, has again been recognized as ...
January 10, 2024 | News
Menarini Silicon Biosystems, a pioneer of liquid biopsy technology, announced today the publication, in the Journal of Clinical Chemistry, of the fina...
January 10, 2024 | News
GC Cell, a fully integrated cell therapy pioneer, is proud to announce the approval from both the Australian Human Research Ethics Committee (HREC) a...
January 09, 2024 | News
First clinical trial to evaluate the safety and efficacy of OBI-992 (a.k.a BSI-992), a novel antibody drug conjugate (ADC) targeting TROP2 - Dosing of f...
January 09, 2024 | News
Dercum's disease is a rare disease characterized by the growth of painful lipomas. The pain can be severe, chronic (> 3 months) and often disabling. So ...
January 09, 2024 | News
Suvoda LLC, a global clinical trial technology company that specializes in complex studies in therapeutic areas like oncology, central nervous system...
January 08, 2024 | News
This will be the second indication for which cadonilimab has received approval in China, following its use as a monotherapy treatment for recurrent or...
January 08, 2024 | News
Most Read
Bio Jobs
News
Editor Picks